FindTrial
Sign In

Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients

Effects of Micronized Trans-resveratrol Treatment on Clinical, Endocrine, Metabolic and Biochemical Parameters of Women With Polycystic Ovary Syndrome: Placebo-controlled Randomized Single-blind Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01720459
Enrollment
40
Registered
2012-11-02
Start date
2012-12-31
Completion date
2014-12-31
Last updated
2012-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome (PCOS)

Brief summary

The purpose of this study is to determine whether micronized trans-resveratrol improves clinical (excessive hair, menstrual cycle), endocrine (androgens)and metabolic (lipids, markers of systemic inflammation) in women with polycystic ovary syndrome (PCOS).

Interventions

DIETARY_SUPPLEMENTMicronized trans-resveratrol
DIETARY_SUPPLEMENTPlacebo

Sponsors

University of California, Davis
CollaboratorOTHER
Poznan University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* PCO - Androgen Excess Society criteria: hyperandrogenism (hirsutism) / hyperandrogenemia (testosterone \>70ng/dl) and/or oligomenorrhea (\<8 spontaneous menses per year) and/or polycystic ovarian morphology on ultrasound * Normal prolactin, TSH, 17-OH progesterone * No evidence of androgen producing malignancy, Cushing's syndrome or acromegaly * Age 18-40

Exclusion criteria

* Use of oral contraceptives and/or other steroid hormones 3 months prior to the study

Design outcomes

Primary

MeasureTime frame
testosterone serum concentration3 month therapy

Countries

Poland

Contacts

Primary ContactBeata Banaszewska, MD PhD
bbeata48@gmail.com+48 61 8419412
Backup ContactRobert Z Spaczynski, MD PhD
rspaczynski@yahoo.com+48 61 8419412

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026